Juan Diego Oms, MD
Psychiatry · Miami, FLNPI 1508067679
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 91.8% of the total across 334 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 334 payments — averaging $36.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$3K
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$1K
- Alkermes, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$815
- plus $3K from 13 others
Across 8 payments — averaging $3596.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$26K
- Indivior Inc.$3K
What the payments were for
- Consulting fees$6605%
- Travel & lodging$2202%
- Food & beverage$11,28892%
- Education$1331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 56 | $2,746 |
| Johnson & Johnson | 54 | $1,870 |
| Otsuka America Pharmaceutical, Inc. | 55 | $1,663 |
| Neurocrine Biosciences, Inc. | 27 | $1,175 |
| Alkermes, Inc. | 39 | $1,050 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 16 | $815 |
| AbbVie(2 entities) | 25 | $769 |
| Indivior Inc. | 26 | $726 |
| E.r. Squibb & Sons, L.L.C. | 14 | $433 |
| Pear Therapeutics (US), Inc. | 4 | $288 |
| Janssen Scientific Affairs, LLC | 2 | $162 |
| Luye Pharma (USA) Ltd. | 3 | $159 |
| Vanda Pharmaceuticals Inc. | 6 | $150 |
| Biogen | 1 | $150 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $61 |
| Noven Therapeutics, LLC | 1 | $24 |
| Braeburn Inc. | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Viiv Healthcare Company | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$930
- INGREZZA$615
- SPRAVATO$575
- CAPLYTA$492
- UZEDY$487
- VRAYLAR$375
- REXULTI$368
- Austedo XR$235
- ARISTADA INITIO$232
- RESET-O$204
- COBENFY$129
- INVEGA SUSTENNA$125
- ERZOFRI EXTENDED-RELEASE$122
How this compares
$12,300 in reported general payments places this provider in the 90th percentile of 2,059 psychiatry providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 12 | $1,367 |
| Hydroxyzine Pamoate | 16 | $128 |
| Trazodone Hcl | 29 | $115 |
| Quetiapine Fumarate | 12 | $89 |
| Escitalopram Oxalate | 13 | $59 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Miami
- Kenny PerezMiami$453K
- Erik CabreraMiami$357K
- Miguel FloresMiami$176K
- Pedro RodriguezMiami$96K
- John NewcomerMiami$96K
- Patricia JunqueraMiami$80K
- Marc AgroninMiami$66K
- Andrew CutlerLakewood Ranch$5.7M
- Richard JacksonBoca Raton$3.6M
- Ilan MelnickCoral Gables$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.